UA103881C2 - Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека - Google Patents

Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека

Info

Publication number
UA103881C2
UA103881C2 UAA200913904A UAA200913904A UA103881C2 UA 103881 C2 UA103881 C2 UA 103881C2 UA A200913904 A UAA200913904 A UA A200913904A UA A200913904 A UAA200913904 A UA A200913904A UA 103881 C2 UA103881 C2 UA 103881C2
Authority
UA
Ukraine
Prior art keywords
prevention
immunodeficiency virus
therapeutic treatment
human immunodeficiency
infection caused
Prior art date
Application number
UAA200913904A
Other languages
English (en)
Ukrainian (uk)
Inventor
Брайан П. Карни
Анита А. Матиас
Original Assignee
Гилиад Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гилиад Сайенсиз, Инк. filed Critical Гилиад Сайенсиз, Инк.
Publication of UA103881C2 publication Critical patent/UA103881C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Изобретения относится к медицине и фармацевтике и касаются применения, композиций и наборов для лечения инфекции, вызванной вирусом иммунодефицита человека, путем общего введения 6-(3-хлор-2-фторбензил)-1-[(2S)-1-гидрокси-3-метилбут-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты или ее фармацевтически приемлемой соли с лопинавиром или его фармацевтически приемлемой солью и ритонавиром или его фармацевтически приемлемой солью.
UAA200913904A 2007-06-29 2008-06-26 Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека UA103881C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94732507P 2007-06-29 2007-06-29
PCT/US2008/068351 WO2009006203A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
UA103881C2 true UA103881C2 (ru) 2013-12-10

Family

ID=39817166

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200913904A UA103881C2 (ru) 2007-06-29 2008-06-26 Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека

Country Status (21)

Country Link
US (4) US20090093482A1 (ru)
EP (1) EP2167089A1 (ru)
JP (3) JP5547067B2 (ru)
KR (1) KR20100028656A (ru)
CN (2) CN101743004A (ru)
AP (1) AP2490A (ru)
AR (1) AR067184A1 (ru)
AU (1) AU2008270634B2 (ru)
BR (1) BRPI0813955A2 (ru)
CA (1) CA2691736A1 (ru)
CO (1) CO6251236A2 (ru)
EA (1) EA200971096A1 (ru)
EC (1) ECSP109889A (ru)
IL (1) IL202745A0 (ru)
MX (1) MX2009013828A (ru)
NZ (1) NZ582089A (ru)
SG (1) SG182228A1 (ru)
TW (1) TW200916103A (ru)
UA (1) UA103881C2 (ru)
WO (1) WO2009006203A1 (ru)
ZA (1) ZA201000468B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635468C (en) * 2005-12-30 2016-08-09 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
CN103275033B (zh) 2006-07-07 2015-04-29 吉里德科学公司 治疗剂的药代动力学特性调节剂
EP2644587A3 (en) 2006-09-12 2013-10-23 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US9891239B2 (en) * 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SG182229A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
EP2555757B1 (en) * 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
WO2012088178A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
JP2015508822A (ja) * 2012-03-01 2015-03-23 ギリアード サイエンシーズ， インコーポレイテッド 噴霧乾燥製剤
CN104520275B (zh) 2012-08-03 2016-11-02 吉利德科学公司 用于制备整合酶抑制剂的方法和中间产物
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
JP6411491B2 (ja) 2013-07-12 2018-10-24 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
NO2865735T3 (ru) 2013-07-12 2018-07-21
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (ru) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
CN107531727B (zh) 2015-04-02 2019-11-29 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
DK1564210T5 (da) * 2002-11-20 2010-05-03 Japan Tobacco Inc 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
US20060111933A1 (en) * 2003-10-09 2006-05-25 Steven Wheeler Adaptive medical decision support system
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
CA2635468C (en) * 2005-12-30 2016-08-09 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
CN103275033B (zh) * 2006-07-07 2015-04-29 吉里德科学公司 治疗剂的药代动力学特性调节剂
EP2644587A3 (en) * 2006-09-12 2013-10-23 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
SG182229A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
US10039718B2 (en) * 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
ZA201000468B (en) 2011-06-29
JP2010532373A (ja) 2010-10-07
JP2015143277A (ja) 2015-08-06
CN103356622A (zh) 2013-10-23
AP2009005083A0 (en) 2009-12-31
CN101743004A (zh) 2010-06-16
IL202745A0 (en) 2010-06-30
US20090093482A1 (en) 2009-04-09
KR20100028656A (ko) 2010-03-12
WO2009006203A1 (en) 2009-01-08
ECSP109889A (es) 2010-03-31
US20110009411A1 (en) 2011-01-13
AR067184A1 (es) 2009-09-30
SG182228A1 (en) 2012-07-30
BRPI0813955A2 (pt) 2017-05-09
JP5769762B2 (ja) 2015-08-26
MX2009013828A (es) 2010-03-10
JP5547067B2 (ja) 2014-07-09
TW200916103A (en) 2009-04-16
US20140343062A1 (en) 2014-11-20
CA2691736A1 (en) 2009-01-08
US20170136000A1 (en) 2017-05-18
JP2013199494A (ja) 2013-10-03
AP2490A (en) 2012-10-04
EA200971096A1 (ru) 2010-08-30
EP2167089A1 (en) 2010-03-31
AU2008270634B2 (en) 2014-01-16
CO6251236A2 (es) 2011-02-21
AU2008270634A1 (en) 2009-01-08
NZ582089A (en) 2013-01-25

Similar Documents

Publication Publication Date Title
UA103881C2 (ru) Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека
MX2009013829A (es) Composiciones terapeuticas y su uso.
PH12018502489A1 (en) Antiviral therapy
MD4754B1 (ru) Полициклические соединения карбамоилпиридона и их фармацевтическое применение
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
MX2010002317A (es) Derivados de indol sustituidos y metodos para su utilizacion.
MX2010005355A (es) Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2010005356A (es) Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
MX2012015293A (es) Derivados de acido 2-quinolinil-acetico como compuestos antivirales.
MX2010002316A (es) Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
PH12015501156A1 (en) Pharmaceutical compositions
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
WO2006085979A3 (en) Soluble forms of hendra and nipah virus g glycoprotein
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
WO2010138419A3 (en) Materials and methods for treating viral infections
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
UA103880C2 (ru) Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека
EA033921B9 (ru) Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа
TH122341A (th) องค์ประกอบและวิธีที่ใช้ในการรักษา
TH122341B (th) องค์ประกอบและวิธีที่ใช้ในการรักษา